Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Vortioxetine in Healthy Subjects
NCT03884491Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoints: Absolute Bioavailability (F) at 72 hours and Time to Maximum Plasma Concentration (tmax) at 72 hours. Started Mar 2019; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03884491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884491.